(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US. Ordspono (odronextamab) has been ...

See the night sky like never before with the best binoculars for stargazing, designed to easily view the planetary parade, total lunar eclipse and more! Binoculars are a great way to get into ...

After hours: February 13 at 6:25:24 PM EST ...